Brystkreft - diagnostikk og behandling ved Ålesund sjukehus

Tidsskrift for den Norske Laegeforening

Volumn 130, Issue 7, 2010, Pages 724-728

  Opsahl, Else Marie ^a   Westre, Bjørn ^b   Samset, Jon Helge ^b   Olafsson, Sverrir ^b   Michelsen, Kåre ^b   Varhaug, Jan Erik ^c  

^a Kirurgisk avdeling Ålesund sjukehus   (Norway)

^b Avdeling for patologi ^*  (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; CARCINOMA IN SITU; FEMALE; HEALTH CARE QUALITY; HUMAN; LYMPHADENECTOMY; MAMMOGRAPHY; MIDDLE AGED; NORWAY; PAGET NIPPLE DISEASE; PATHOLOGY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; GUIDELINE ADHERENCE; HUMANS; LYMPH NODE EXCISION; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NORWAY; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 77951632083     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.0155     Document Type: Article

References (20)

1. Kvalitetsmanual Mammografiprogrammet. Oslo: Kreftregisteret, 2003. www.kreftregisteret.no/Global/Kvalitetsmanualer/kvalitetsmanual_mammografiprogrammet.pdf (27.1. 2009).
2. Blåboka. NBCC behandlingsanbefalinger. Oslo 1981, januar 2007. Siste revisjon i styringsgruppemøte juni 2009. www.nbcg.no (27.1. 2009).
3. Rampaul RS, Pinder SE, Robertson JF et al. Assessment of HER2 and its value in breast cancer. Kap. 12. I: Walker RA, red. Prognostic and predictive factors in breast cancer. London: Martin Dunitz, 2003.
4. Penault-Llorca F, André F, Sagen C et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2809-15.
5. Yau TK, Sze H, Soong IS et al. HER2 overexpression of breast cancer in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridization assays. Hong Kong Med J 2008; 14: 333.
6. Naik AM, Fey J, Gemignami M et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. A follow-up study of 4008 procedures. Ann Surg 2004; 240: 462-71.
7. Chung A, Yu J, Stempel M et al. Is the «10% rule» equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol 2000; 15: 2728-33.
8. Schlichting E, Harr ME, Sauer T et al. Vaktpostlymfeknuteoperasjon ved brystkreft. Tidsskr Nor Lægeforen 2006; 126: 2098-100.
9. Noguchi M. Sentinel lymph node biopsy and breast cancer. Br J Surg 2002; 89: 21-34.
10. Rodier JF, Velten M, Wilt M et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures; FRANSENODE trial. J Clin Oncol 2007; 25: 3664-9.
11. Yi M, Meric-Bernstam, Ross M I et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer 2008; 113: 30-7.
12. Wang H, Hofvind S, Thoresen S. Prøveprosjekt med mammografi - resultater fra første undersøkelsesrunde. Tidsskr Nor Lægeforen 2000; 120: 3237-40.
13. Iversen B, Eriksen L. Mammografiscreening i Rogaland - første runde. Tidsskr Nor Lægeforen 2000; 120: 3241-5.
14. Park D, Kåresen R, Beraki E et al. Mikrometastaser til aksilære lymfeknuter hos brystkreftpasienter med kjent mikrometastasestatus i benmarg og kjent klinisk forløp. Abstrakt 246. Oslo: De norske kirurgiske foreninger. Vitenskaplige forhandlinger, 2008.
15. EBCTCG. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomized trials. Lancet 2005; 366: 2087-106.
16. Langer I, Guller U, Berclaz G et al. Morbidity of sentinel node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery. Ann Surg 2007; 245: 452-61.
17. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-41.
18. Vatne M, Opsahl EM, Aas T et al. Brystbevarende kirurgi ved Haukeland Universitetssykehus 1985-95; oppfølging av materiale. Abstrakt 247. Oslo: De norske kirurgiske foreninger. Vitenskaplige forhandlinger, 2008.
19. Poletti P, Fenaroli P, Milesi A et al. Axillary recurrence in sentinel lymph node-negative breast cancer patients. Ann Oncol 2008; 19: 1842-6.
20. Kalager M, Haldorsen T, Bretthauer M et al. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women. A populationbased cohort study. Breast Cancer Res 2009; 11: R44.